Hyperthermia


What is hyperthermia?

The term hyperthermia refers to raising the temperature of a part of or the whole body above normal for a defined period of time. The amount of temperature elevation is on the order of a few degrees above normal temperature (41,0 - 42.5 C°).

History

Written reports concerning the use of increased temperatures in cancer treatment have existed for many centuries. Probably the oldest report was found in the Egyptian Edwin Smith surgical papyrus, dated around 3000 BC. Hyperthermia researchers like to cite Hippocrates (460-370 BC) in particular, although the method he describes in one of his aphorisms, i.e. hot irons, concerns higher temperatures, such as those used in cauterisation. In the 19th century Dr. W. Coley treated patients with an extracted bacterial toxin from erysipelas, which causes high fevers. This was after observations that some cancers appeared to resolve after prolonged infection with erysipelas. In 1898, a Swedish physician, Dr. Westermark described anecdotal incidences of local hyperthermia causing cervical cancer to regress.

Rationale for hyperthermia in cancer treatment

Selective effect

A selective tumour cell killing effect is achieved at temperatures between 40 and 44°C, which is related to a characteristic difference between normal and tumour physiology. The architecture of the vasculature in solid tumours is chaotic, resulting in regions with hypoxia and low pH, which is not found in normal tissues in undisturbed conditions. These environmental factors make cells more sensitive to hyperthermia. The effect of hyperthermia depends on the temperature and the exposure time. Most normal tissues are undamaged by treatment for 1 h at a temperature of up to 44°C. Only nervous tissues appear more sensitive.

Mechanism of cell death

The main mechanism for cell death is probably protein denaturation, observed at temperatures >40°C, which leads to alterations in molecular structures like cytoskeleton and membranes, and changes in enzyme complexes for DNA synthesis and repair.

Combination of hyperthermia with chemotherapy

    For the combination of hyperthermia and chemotherapy, spatial cooperation can explain the additive effects.
  • the efficacy of many drugs is potentiated by heat.
  • the addition of hyperthermia to chemotherapy can counteract drug resistance.
  • Increase in intracellular drug uptake
  • enhanced DNA damage
  • increase in intratumour drug concentrations, resulting from an increase in blood flow.
Whether the clinical combination of hyperthermia and chemotherapy leads to therapeutic gain will depend on the temperature increase in the organs for which the used drug is toxic. Hyperthermia is thought to affect tumour sensitivity to other treatments mainly through microenvironmental factors such as pH. One hypothesis is that hypoxic and therefore resistant tumour regions are preferentially eliminated under hyperthermic conditions because associated hypovascularisation results in higher temperatures and higher sensitivity due to hypoxia.

Heat shock proteins

Heat shock proteins (HSPs) are synthesised in response to stress such as a hyperthermic treatment. After a non-lethal heat shock, HSPs were found to be expressed on the surface of malignant cells but not on normal cells. HSP-expressing cells are more susceptible to lysis by natural killer effector cells. HSPs are released following necrotic cell death, and released HSPs stimulate macrophages and dendritic cells to secrete cytokines, and activate antigen-presenting cells.

Toxicity

Normal tissue toxicity will result directly from hyperthermia when the tolerance limits are exceeded. Experimental studies have shown that most normal tissues are not damaged when the temperature over 1 h of treatment does not exceed 44°C. Whether the toxicity of chemotherapy is enhanced will depend on the temperature in the drug-sensitive tissues.
The cellular damage by hyperthermia is most dramatic when the temperature is elevated to 43° C or higher in the intended tissue. The cells are most sensitive to heat in the late S phase (DNA synthesis phase) of the cell cycle.
    References
  • 1. Seegenschmiedt MH, Vernon CC. A historical perspective on hyperthermia in oncology. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds):Thermoradiotherapy and Thermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 3-44.
  • 2. Reinhold HS, Endrich B. Tumour microcirculation as a target for hyperthermia. Int J Hyperthermia 1986; 2: 111-137.
  • 3. Song VE, Choi IB, Nah BS et al. Microvasculature and perfusion in normal tissues and tumours. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds):Thermoradiotherapy and Thermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 139-156.
  • 4. Vaupel PW, Kelleher DK. Metabolic status and reaction to heat of normal and tumor tissue. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds):Thermoradiotherapy and Thermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 157-176.
  • 5. Raaphorst GP. Fundamental aspects of hyperthermic biology. In Field SB, Hand JW (eds): An Introduction to the Practical Aspects of Clinical Hyperthermia. London: Taylor and Francis 1990; 10-54.
  • 6. Fajardo LF. Pathological effects of hyperthermia in normal tissues. Cancer Res 1984; 44: 4826s-4835s.[Abstract]
  • 7. Sminia P, Van der Zee J, Wondergem J, Haveman J. Effect of hyperthermia on the central nervous system: a review. Int J Hyperthermia 1994; 10:1-130.[Medline]
  • 8. Wondergem J, Haveman J, Rusman V et al. Effects of local hyperthermia on the motor function of the rat sciatic nerve. Int J Radiat Biol 1988; 53: 429-439.
  • 9. Streffer C. Molecular and cellular mechanisms of hyperthermia. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy and Thermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 47-74.
  • 10. Song CWM, Shakil A, Griffin RJ, Okajima K. Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination with carbogen. Semin Oncol 1997; 24: 626-632.[Medline]
  • 11. Kampinga HH, Dikomey E. Hyperthermic radiosensitization: mode of action and clinical relevance. Int J Radiat Biol 2001; 77: 399-408.[Medline]
  • 12. Stewart FA, Denekamp J. The therapeutic advantage of combined heat and X-rays on a mouse fibrosarcoma. Br J Radiol 1978; 51: 307-316.[Abstract]
  • 13. Marino C, Cividalli A. Combined radiation and hyperthermia: effects of the number of heat fractions and their interval on normal and tumour tissues. Int J Hyperthermia 1992; 8: 771-781.[Medline]
  • 14. Horsman MR, Overgaard J. Simultaneous and sequential treatment with radiation and hyperthermia: a comparative assessment. In Handl-Zeller L (ed.):Interstitial Hyperthermia. Vienna: Springer Verlag 1992; 11-33.
  • 15. Dahl O. Interaction of heat and drugs in vitro and in vivo. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy and Thermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 103-121.
  • 16. Skibba JL, Jones FE, Condon RE. Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. Cancer Treat Rep 1982; 66: 1357-1363.[Medline]
  • 17. Ostrow S, Van Echo D, Egorin M et al. Cyclophosphamide pharmacokinetics in patients receiving whole-body hyperthermia. Natl Cancer Inst Monogr 1982; 61: 401-403.
  • 18. Honess DJ, Donaldson J, Workman P, Bleehen NM. The effect of systemic hyperthermia on melphalan pharmocokinetics in mice. Br J Cancer 1985; 51:77-84.[Medline]
  • 19. Bates DA, Mackillop WJ. The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro. Br J Cancer 1990; 62: 183-188.[Medline]
  • 20. Myerson RJ, Moros E, Roti Roti JL. Hyperthermia. In Perez CA, Brady LW (eds): Principles and Practice of Radiation Oncology, 3rd edition. Philadelphia:Lippincott-Raben Publishers 1997; 637-683.
  • 21. Coit DG. Hyperthermic isolation limb perfusion for malignant melanoma: a review. Cancer Invest 1992; 10: 277-284.[Medline]
  • 22. Ceelen WP, Hesse U, De Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 2000; 87: 1006-1015.[Medline]
  • 23. Robins HI, on behalf of SHOWG members. Meeting report. Systemic Hyperthermia Oncological Working Group. Oncology 1995; 52: 260-263.[Medline]
  • 24. Robins HI, Dennis WH, Neville AJ et al. A nontoxic system for 41.8°C whole-body hyperthermia: results of a phase I study using a radiant heat device. Cancer Res 1985; 45: 3937-3944.[Abstract]
  • 25. Bull JCM. Clinical practice of whole-body hyperthermia: new directions. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy and Thermochemotherapy Volume 2. Berlin: Springer Verlag 1996; 303-322.
  • 26. Cavaliere R, Ciocatto EC, Giovanella BC et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20:1351-1381.[Medline]
  • 27. Pettigrew RT, Galt JM, Ludgate CM, Smith AN. Clinical effects of whole-body hyperthermia in advanced malignancy. Br Med J 1974; 4: 679-682.[Medline]
  • 28. Kim JH, Hahn EW, Tokita N, Nisce LZ. Local tumor hyperthermia in combination with radiation therapy. 1. Malignant cutaneous lesions. Cancer 1977; 40:161-169.[Medline]
  • 29. González González D, Van Dijk JDP, Blank LECM, Rümke PH. Combined treatment with radiation and hyperthermia in metastatic malignant melanoma. Radiother Oncol 1986; 6: 105-113.[Medline]
  • 30. Hetzel FW, Mattiello J. Interactions of hyperthermia with other modalities. In Paliwal BR, Hetzel FW, Dewhirst MW (eds): Medical Physics Monograph no. 16. Biological, Physical and Clinical Aspects of Hyperthermia. College Park, MD: American Institute of Physics 1987; 30-56.
  • 31. Manning MR, Cetas TC, Miller RC et al. Clinical hyperthermia: results of a phase I trial employing hyperthermia alone or in combination with external beam or interstitial radiotherapy. Cancer 1982; 49: 205-216.[Medline]
  • 32. Dunlop PRC, Hand JW, Dickinson RJ, Field SB. An assessment of local hyperthermia in clinical practice. Int J Hyperthermia 1986; 2: 39-50.[Medline]
  • 33. Gabriele P, Orecchia R, Ragona R et al. Hyperthermia alone in the treatment of recurrences of malignant tumors. Cancer 1990; 66: 2191-2195.[Medline]
  • 34. Van der Zee J, Treurniet-Donker AD, The SK et al. Low dose reirradiation in combination with hyperthermia: a palliative treatment for patients with breast cancer recurring in previously irradiated areas. Int J Radiat Oncol Biol Phys 1988; 15: 1407-1413.[Medline]
  • 35. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989; 16: 535-549.[Medline]
  • 36. Van der Zee J, Vernon CC. Thermoradiotherapy for advanced and recurrent breast tumours. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds):Thermoradiotherapy and Thermochemotherapy Volume 2. Berlin: Springer Verlag 1996; 35-48.
  • 37. Van der Zee J, Van der Holt B, Rietveld PJM et al. Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation. Br J Cancer 1999; 79: 483-490.[Medline]
  • 38. Rietbroek RC, Schilthuis MS, Bakker PJM et al. Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer 1997; 79: 935-943.[Medline]
  • 39. De Wit R, Van der Zee J, Van der Burg MEL et al. A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix. Br J Cancer 1999; 80: 1387-1391.[Medline]
  • 40. Issels RD, Abdel-Rahman S, Wendtner C-M et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 2001; 37: 1599-1608.[Medline]
  • 41. Wendtner C-M, Abdel-Rahman S, Baumert J et al. Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults:results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 2001; 37: 1609-1616.[Medline]
  • 42. Westermann AM, Grosen EA, Katschinski DM et al. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur J Cancer 2001; 37: 1111-1117.[Medline]
  • 43. Wiedemann GJ, Robins HI, Gutsche S et al. Ifosfamide, carboplatin and etoposid (ICE) combined with 41.8°C whole body hyperthermia in patients with refractory sarcoma. Eur J Cancer 1996; 32A: 888-892.
  • 44. Van Heek R, D'Oleire F, Havers W. Thermoradiotherapy and thermochemotherapy for pediatric tumors. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy and Thermochemotherapy Volume 2. Berlin: Springer Verlag 1996; 187-205.
  • 45. Wessalowski R, Ruck H, Pape H et al. Hyperthermia for the treatment of patients with malignant germ cell tumors. A phase I/II study in ten children and adolescents with recurrent or refractory tumors. Cancer 1998; 82: 793-800.[Medline]
  • 46. Perez CA, Gillespie B, Pajak T et al. Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a report by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1989; 16: 551-558.[Medline]
  • 47. Perez CA, Pajak T, Emami B et al. Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Final report by the Radiation Therapy Oncology Group. Am J Clin Oncol 1991; 14: 133-141.[Medline]
  • 48. Emami B, Scott C, Perez CA et al. Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors: a prospectively controlled randomized study by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1996; 34:1097-1104.[Medline]
  • 49. Valdagni R, Amichetti M, Pani G. Radical radiation alone versus radical radiation plus microwave hyperthermia for N3 (TNM-UICC) neck nodes: a prospective randomized clinical trial. Int J Radiat Oncol Biol Phys 1988; 15: 13-24.[Medline]
  • 50. Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymphnodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 1993; 28: 163-169.
  • 51. Overgaard J, González González D, Hulshof MCCM et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 1995; 345: 540-543.[Medline]
  • 52. Vernon CC, Hand JW, Field SB et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996; 35: 731-744.[Medline]
  • 53. Sneed PK, Stauffer PR, McDermott W et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 287-295.[Medline]
  • 54. Van der Zee J, González González D, Van Rhoon GC et al. for the Dutch Deep Hyperthermia Group. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet 2000; 355: 1119-1125.[Medline]
  • 55. Berdow BA, Menteshashvili GZ. Thermoradiotherapy of patient with locally advanced carcinoma of the rectum. Int J Hyperthermia 1990; 6:881-890.[Medline]
  • 56. Colombo R, Da Pozzo LF, Gev A et al. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996; 155: 1227-1232.[Medline]
  • 57. Datta NR, Bose AK, Kapoor HK. Thermoradiotherapy in the management of carcinoma cervix (stage IIIb): a controlled clinical study. Indian Med Gazette 1987; 121: 68-71.
  • 58. Egawa S, Tsukiyama I, Watanabe S et al. A randomized clinical trial of hyperthermia and radiation versus radiation alone for superficially located cancers. J Jpn Soc Ther Radiol Oncol 1989; 1: 135-140.
  • 59. Engelhardt R, Neumann H, Müller U, Löhr GW. Clinical studies in whole body hyperthermia. In Sugahara T, Saito M (eds): Hyperthermic Oncology Volume 2. London: Taylor and Francis 1989; 509-510.
  • 60. Harima Y, Nagata K, Harima K et al. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIb cervical carcinoma. Int J Hyperthermia 2001; 17: 97-105.[Medline]
  • 61. Kakehi M, Ueda K, Mukojima T et al. Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer of deep-seated organs. Int J Hyperthermia 1990; 6: 719-740.[Medline]
  • 62. Kitamura K, Kuwano H, Watanabe M et al. Prospective randomized study of hyperthermia combined with chemoradiotherapy for esophageal carcinoma. J Surg Oncol 1995; 60: 55-58.[Medline]
  • 63. Kohno I, Kaneshige E, Fujiwara K, Sekiba K. Thermochemotherapy (TC) for gynecologic malignancies. In Overgaard J (ed.): Hyperthermic Oncology Volume 1. London: Taylor and Francis 1984; 753-756.
  • 64. Strotsky AV, Fradkin SZ, Zhavrid EA, Karpovich UA. Combined therapy of bladder cancer with the use of hyperthermia. Strahlenther Onkol 1991; 167:346.
  • 65. Sugimachi K, Kitamura K, Baba K et al. Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus: a prospective randomized trial. Int J Hyperthermia 1992; 8: 289-295.[Medline]
  • 66. Wang J, Li D, Chen N. Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer. Chung Hua Chung Liu Tsa Chih 1996; 18: 51-54.[Medline]
  • 67. You Q-S, Wang R-Z, Suen G-Q et al. Combination preoperative radiation and endocavitary hyperthermia for rectal cancer: long-term results of 44 patients. Int J Hyperthermia 1993; 9: 19-24.[Medline]
  • 68. Datta NR, Bose AK, Kapoor HK, Gupta S. Head and neck cancers: results of thermoradiotherapy versus radiotherapy. Int J Hyperthermia 1990; 6:479-486.[Medline]
  • 69. Marmor JB, Hahn GM. Combined radiation and hyperthermia in superficial human tumors. Cancer 1980; 46: 1986-1991.[Medline]
  • 70. Sharma S, Patel FD, Sandhu APS et al. A prospective randomized study of local hyperthermia as a supplement and radiosensitizer in the treatment of carcinoma of the cervix with radiotherapy. Endocuriether Hyperthermia Oncol 1989; 5: 151-159.
  • 71. Shchepotin IB, Evans SRT, Chorny V et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. Surg Oncol 1994; 3: 37-44.[Medline]
  • 72. Sugimachi K, Kuwano H, Ide H et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial. Int J Hyperthermia 1994; 4: 485-493.
  • 73. Lee HK, Antell AG, Perez CA et al. Superficial hyperthermia and irradiation for recurrent breast carcinoma of the chest wall: prognostic factors in 196 tumors. Int J Radiat Oncol Biol Phys 1998; 40: 365-375.[Medline]
  • 74. Hiraoka M, Jo S, Akuta K et al. Radiofrequency capacitive hyperthermia for deep-seated tumors II. Effect of thermoradiotherapy. Cancer 1987; 60:128-135.[Medline]
  • 75. Lee CK, Song CW, Rhee JG et al. Clinical experience using 8 MHz radiofrequency capacitive hyperthermia in combination with radiotherapy: results of a phase I/II study. Int J Radiat Oncol Biol Phys 1995; 32: 733-745.[Medline]
  • 76. Wust P, Stahl H, Löffel J et al. Clinical, physiological and anatomical determinants for radiofrequency hyperthermia. Int J Hyperthermia 1995; 11:151-167.[Medline]
  • 77. Cavaliere R, Di Filippo F, Cavaliere F et al. Clinical practice of hyperthermic extremity perfusion in combination with radiotherapy and chemotherapy. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy and Thermochemotherapy Volume 2. Berlin: Springer Verlag 1996; 323-345.
  • 78. Van der Zee J, González González D. The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia 2002; 18: 1-12.[Medline]
  • 79. Wust P, Fahling H, Helzel T et al. Design and test of a new multi-amplifier system with phase and amplitude control. Int J Hyperthermia 1998; 14: 459-477.
  • 80. Van Rhoon GC, Rietveld PCM, Van der Zee J. A 433 MHz Lucite Cone waveguide applicator for superficial hyperthermia. Int J Hyperthermia 1998; 14:13-27.[Medline]
  • 81. Rietveld PJM, Van Putten WLJ, Van der Zee J, Van Rhoon GC. Comparison of the clinical effectiveness of the 433 MHz Lucite Cone applicator with that of a conventional waveguide applicator in applications of superficial hyperthermia. Int J Radiat Oncol Biol Phys 1999; 43: 681-687.[Medline]
  • 82. Jordan A, Scholz R, Maier-Hauff K et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia. J Magnetism Magn Mat 2001; 225: 118-126.
  • 83. Wust P, Seebass M, Nadobny J et al. Simulation studies promote technological development of radiofrequency phased array hyperthermia. Int J Hyperthermia 1996; 12: 477-494.[Medline]
  • 84. Lagendijk JJW. Hyperthermia treatment planning. Phys Med Biol 2000; 45: R61-R76.[Medline]
  • 85. Gellermann J, Wust P, Stalling D et al. Clinical evaluation and verification of the hyperthermia treatment planning system Hyperplan. Int J Radiat Oncol Biol Phys 2000; 47: 1145-1156.[Medline]
  • 86. Carter DL, MacFall JR, Clegg ST et al. Magnetic resonance thermometry during hyperthermia for human high-grade sarcoma. Int J Radiat Oncol Biol Phys 1998; 40: 815-822.[Medline]
  • 87. Hentschel M, Dreher W, Wust P et al. Fast spectroscopic imaging for non-invasive thermometry using the Pr[MOE-DO3A] complex. Phys Med Biol 1999; 44:2397-2408.[Medline]
  • 88. Yatvin MB, Mühlensiepen H, Porschen W et al. Selective delivery of liposome-associated cis-Dichlorodiammineplatinum(II) by heat and its influence on tumor drug uptake and growth. Cancer Res 1981; 41: 1602-1607.[Abstract]
  • 89. Matteucci ML, Anyarambhatla G, Rosner G et al. Hyperthermia increases accumulation of Technetium-99M-labeled liposomes in feline sarcomas. Clin Cancer Res 2000; 6: 3748-3755.[Abstract/Free Full Text]
  • 90. Kong G, Anyarambhatla G, Petros WP et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000; 60: 6950-6957.[Abstract/Free Full Text]
  • 91. Multhoff G, Botzler C, Wiesnet M et al. A stress-indcible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 1995; 61: 272-279.[Medline]
  • 92. Multhoff G, Botzler C, Wiesnet M et al. CD-3 large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood 1995; 86: 1374-1384.[Abstract/Free Full Text]
  • 93. Basu S, Binder RJ, Suto R et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-B pathway. Int Immunol 2000; 12: 1539-1546.[Abstract/Free Full Text]
  • 94. Ito A, Shinkai M, Honda H et al. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001; 50: 515-522.[Medline]
  • 95. Gerner EW, Hersh EM, Pennington M et al. Heat-inducible vectors for use in gene therapy. Int J Hyperthermia 2000; 16: 171-181.[Medline]
  • 96. Huang Q, Hu JK, Lohr F et al. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res 2000; 60:3435-3439.[Abstract/Free Full Text]
  • 97. Okamota K, Shinoura N, Egawa N et al. Adnovirus-mediated transfer of p53 augments hyperthermia-induced apoptosis in U251 glioma cells. Int J Radiat Oncol Biol Phys 2001; 50: 525-531.[Medline]
  • 98. Lohr F, Hu K, Huang Q et al. Enhancement of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys 2000; 48:1513-1518.[Medline]
  • 99. Benowitz S. Bone marrow experts are still debating the value of purging. J Natl Cancer Inst 2000; 92: 190-192.[Free Full Text]
  • 100. Moriyama Y, Narita M, Sato K et al. Application of hyperthermia to the treatment of human acute leukemia: purging human leukemic progenitor cells by heat. Blood 1986; 67: 802-804.[Abstract]
  • 101. Iwasawa T, Hirabayashi Y, Kubota N et al. Hyperthermic purging in vitro of murine leukemia cells (MK-8057): surviving fractions of normal and leukemic stem cells and the long-term survival of mice injected with the post-hyperthermic leukemia cells. Exp Hematol 1991; 19: 332-337.[Medline]
  • 102. Osman Y, Moriyama Y, Shibata A. Enhanced elimination of Ph+ chormosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-, TNF,
  • and quercetin): its application to autologous bone marrow transplantation for CML. Exp Hematol 1995; 23: 444-452.[Medline]
  • 103. Wierenga PK, Setroikromo R, Vellenga E, Kampinga HH. Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH[3]. Br J Haematol 2000; 111: 1145-1152.[Medline]
  • 104. Griffin RJ, Ogawa A, Song CW. A novel drug to reduce tumor perfusion: antitumor effect alone and with hyperthermia. Radiat Res 2000; 154:202-207.[Medline]
  • 105. Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001; 40: 497-503.[Medline]
  • 106. Eikesdal HP, Bjerkvig R, Dahl O. Vinblastine and hyperthermia target the neovasculature in BT4AN rat gliomas: therapeutic implications of the vascular phenotype. Int J Radiat Oncol Biol Phys 2001; 51: 535-544.[Medline]
  • 107. Eikesdal HP, Bjerkvig R, Mella O, Dahl O. Combrestatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiother Oncol 2001; 60: 147-154.[Medline]
  • 108. Kai H, Matsufuji H, Okudaira Y, Sugimachi K. Heat, drugs and radiation given in combination is palliative for unresectable esophageal cancer. Int J Radiat Oncol Biol Phys 1988; 14: 1147-1152.[Medline]
  • 109. Ohno S, Tomoda M, Tomisaki S et al. Improved surgical results after combining preoperative hyperthermia with chemotherapy and radiotherapy for patients with carcinoma of the rectum. Dis Colon Rectum 1997; 40: 401-406.[Medline]
  • 110. Rau B, Wust P, Hohenberger P et al. Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer. A phase II clinical study. Ann Surg 1998; 227: 380-389.[Medline]
  • 111. Anscher MS, Lee C, Hurwitz H et al. A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. Int J Radiat Oncol Biol Phys 2000; 47: 719-724.[Medline]
  • 112. Serin M, Erkal HS, Cakmak A. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with carcinomas of the head and neck with N2 or N3 metastatic cervical lymph nodes. Radiother Oncol 1999; 50: 103-106.[Medline]
  • 113. Feyerabend T, Wiedemann GJ, Jäger B et al. Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease. Int J Radiat Oncol Biol Phys 2001; 49: 1317-1325.[Medline]
  • 114. Hahn GM. Introduction. In Urano M, Douple E (eds): Hyperthermia and Oncology, Volume 4. Utrecht, The Netherlands: VSP 1994: 1-7.